References
- Speight J, Barendse SM. FDA guidance on patient reported outcomes. BMJ 340, c2921 (2010).
- Sloan JA, Halyard MY, Frost MH, Dueck AC, Teschendorf B, Rothman ML; Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. The Mayo Clinic manuscript series relative to the discussion, dissemination, and operationalization of the Food and Drug Administration guidance on patient-reported outcomes. Value Health 10 Suppl 2, S59–S63 (2007).
- Revicki DA; Regulatory Issues and Patient-Reported Outcomes Task Force for the International Society for Quality of Life Research. FDA draft guidance and health-outcomes research. Lancet 369(9561), 540–542 (2007).
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67(6), 361–370 (1983).
- Sheehan DV. The Anxiety Disease. Scribner’s, New York, NY, USA (1983).
- DeMuro C, Clark M, Mordin M, Fehnel S, Copley-Merriman C, Gnanasakthy A. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010. Value Health 15(3), 443–448 (2012).
- Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health 15(3), 437–442 (2012).
- Norquist JM, Girman C, Fehnel S, DeMuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual. Life Res. 21(6), 1013–1020 (2012).
- Willke RJ, Burke LB, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control. Clin. Trials 25(6), 535–552 (2004).
- Gnanasakthy A, DeMuro C, Boulton C. Integration of patient-reported outcomes in multiregional confirmatory clinical trials. Contemp. Clin. Trials 35(1), 62–69 (2013).
- Gnanasakthy A, Doward L, Clark M, Mordin M, DeMuro C. Concordance of PRO labeling claims between the FDA and EMA. Presented at: ISPOR 15th Annual European Congress. Berlin, Germany, November 2012.
- Boumil MM. Off-label marketing and the First Amendment. N. Engl. J. Med. 368(2), 103–105 (2013).
- Baldwin M, Spong A, Doward L, Gnanasakthy A. Patient-reported outcomes, patient-reported information: from randomized controlled trials to the social web and beyond. Patient 4(1), 11–17 (2011).
Websites
- US Department of Health and Human Services. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. (2009). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (Accessed 22 May 2013)
- The Pink Sheet. Patient reported outcomes poised for takeoff after final FDA guidance (2010). www.elsevierbi.com/Publications/The-Pink-Sheet/72/004/Patient-Reported-Outcomes-Poised-For-Takeoff-After-Final-FDA-Guidance?result=1&total=1&searchquery=%253fq%253d00720040011 (Accessed 22 May 2013)
- Adcetris prescribing information. (2011). www.accessdata.fda.gov/drugsatfda_docs/label/2011/125388s000,125399s000lbl.pdf (Accessed 22 May 2013)
- US Department of Health and Human Services. Guidance for industry. Qualification process for drug development tools. (2010). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf (Accessed 27 May 2013)
- United BioSource Corporation. EXACT-PRO Initiative (2013). www.exactproinitiative.com/default.php (Accessed 22 May 2013)
- Center for Drug Evaluation and Research. Application number: 203188Orig1s000 medical review(s) (2011). www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203188Orig1s000MedR.pdf (Accessed 22 May 2013)
- Thomas N; Capital Reporting Company. Meeting of the Advisory Committee for Reproductive Health Drugs (2012). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM303956.pdf (Accessed 22 May 2013)
- European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life measures in the evaluation of medicinal products. (2006). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf (Accessed 22 May 2013)
- European Medicines Agency. Qualification of novel methodologies for drug development: guidance to applicants. (2012). www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004201.pdf (Accessed 22 May 2013)